Sapient Bioanalytics awarded two U.S. patents for its novel machine learning-powered mass spectrometry (MS) methodologies

October 16, 2025 – San Diego, CA – Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has been awarded two United States patents for its pioneering work innovating mass spectrometry (MS) methodologies to enhance how raw MS data is processed, filtered, and interpreted across large-scale biological datasets.

The patents – which include Patent No. US 12,437,980 and Patent No. US 12,437,981 – cover advanced approaches to mass spectrometry signal processing and data normalization, aimed at increasing the accuracy of signal (biomarker) identification across experiments encompassing thousands of biological samples. These innovations form the foundation of data processing in Sapient’s rapid liquid chromatography-mass spectrometry (rLC-MS) pipeline and include image-based signal processing and machine learning (ML)-based feature filtering to distinguish true signals from noise. The Sapient rLC-MS system also automatically detects and corrects for batch effects, normalizing variations in signal intensity that stem from differing experimental conditions to ensure consistent signal interpretation across experimental runs.

These patented innovations improve the functionality and utility of MS for drug discovery and development by expediting and automating large-scale data processing while significantly increasing specificity and sensitivity in identifying biological signals that represent biomarkers of health, disease, and drug response.

“Advanced software frameworks are increasingly central to unlocking the full potential of multi-omics data, and we’re proud to contribute novel computational methodologies that enhance the fidelity, scalability, and interpretability of MS datasets,” said Dr. Mo Jain, Founder and Chief Scientific Officer at Sapient. Dr. Jain is one of the three inventors named on the patent, alongside his Sapient colleagues Dr. Saumya Tiwari, Co-Founder and Head of Computational R&D Operations, and Dr. Jeramie Watrous, Co-Founder and Head of Analytical R&D.

“Mass spectrometry has long been considered a powerful tool for high resolution chemical analysis, but its full potential is often limited by challenges with reproducibility and throughput,” said Dr. Watrous. “With our now patented methodologies, we have overcome those issues to enable more reliable and scalable biochemical profiling across thousands of biosamples.”

Added Dr. Tiwari: “The raw data generated by MS is vast, but its true value remains locked without sophisticated computational keys. Our innovations combine advanced signal processing and machine learning with the rigor of analytical chemistry to build those keys. These intelligent algorithms dramatically improve specificity and sensitivity in biochemical signal detection in LC-MS data, forming the foundation for reliable biomarker discovery. These patents reflect our commitment to developing scalable, high-impact computational systems that transform complex raw data into actionable insights.”

###

About Sapient

Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development.

Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company’s DynamiQ™ Insights Engine — a longitudinal database of integrated multi-omics and real-world data collected from tens of thousands of samples — enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit sapient.bio.

Media Contact:
Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010